All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
San Francisco-based startup Cloudcath has raised a $12 million series A round to support commercialization of its first product that enables remote, real-time monitoring for at-home peritoneal dialysis patients. The expectation is that the notifications it offers to health care providers will enable earlier intervention to avoid complications, including infection. The Cloudcath system is pending U.S. FDA clearance.
Mark Tepper, the founder of newly launched Eumentis Therapeutics Inc., plans to use the company’s recent $2 million Small Business Innovation Research (SBIR) grant to fund IND-enabling studies for EM-036, a nitro-aminoadamantane N-methyl-D-aspartate receptor antagonist to treat Alzheimer's disease and autism spectrum disorders.
Christian Peters, CEO of the newly launched and privately held Pinpoint Therapeutics Inc., said he has a relatively unusual pedigree that allows him a unique perspective in drug development. That combination of working in academia and in the corporate sphere has given him a more well-rounded view than most.
Privately held Sonoma Biotherapeutics Inc. plans to take its newly raised $40 million series A financing to develop regulatory T-cell therapies to control inflammatory responses in autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis.
In its first step into Japan, Agex Therapeutics Inc. accelerates its development of engineering hypoimmunogenic cells, universal cells that can be used on patients who didn’t generate the original cell and without the need to use immunosuppressants.
HONG KONG – South Korean biotech Novelty Nobility Inc. has attracted ₩10 billion (US$9 million) in series A funding to develop therapeutic antibodies inhibiting the stem cell factor (SCF)/c-KIT pathway.
PERTH, Australia – With new funding in hand from Yamaha Motor Ventures & Laboratory Silicon Valley Inc., Loop+ founders and sisters Kath Hamilton and Clare Conroy and are on their way to commercializing a pressure and movement tracking device they developed for wheelchair-bound patients.
TORONTO – Calgary, Alberta-based Orpyx Medical Technologies Inc. has launched a sensory insole with remote patient monitoring to prevent potentially fatal diabetic foot ulcers (DFU) and neuropathy-related ulcers. According to Orpyx CEO Breanne Everett, development of the Orpyx SI sensory insole system follows years of study on how DFUs occur and how best to share information with patients and doctors so they can react quickly to first signs of the condition.
In its first step into Japan, Agex Therapeutics Inc. accelerates its development of engineering hypoimmunogenic cells, universal cells that can be used on patients who didn’t generate the original cell and without the need to use immunosuppressants.
When they work, T cells work great. And the folks at Avidea Technologies Inc. want to make them work more often. Combining expertise in immunology and polymer chemistry, the Baltimore-based startup is developing antigen delivery technology to improve T cell-targeted vaccines.
RSS
